1. Search Result
Search Result
Results for "

cyclic-AMP

" in MedChemExpress (MCE) Product Catalog:

75

Inhibitors & Agonists

1

Biochemical Assay Reagents

20

Peptides

8

Natural
Products

3

Recombinant Proteins

3

Isotope-Labeled Compounds

9

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1511
    Cyclic AMP
    10+ Cited Publications

    cyclic adenosine monophosphate; Adenosine cyclic 3', 5'-monophosphate; cAMP

    Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes .
    Cyclic AMP
  • HY-B1511A
    Cyclic AMP sodium
    10+ Cited Publications

    cyclic adenosine monophosphate sodium; Adenosine cyclic 3', 5'-monophosphate sodium; cAMP sodium; cyclic AMP sodium

    Biochemical Assay Reagents Neurological Disease Metabolic Disease Cancer
    Cyclic AMP (Cyclic adenosine monophosphate) sodium, adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP sodium is an important second messenger in many biological processes .
    Cyclic AMP sodium
  • HY-B1511R

    cyclic adenosine monophosphate (Standard); Adenosine cyclic 3', 5'-monophosphate (Standard); cAMP (Standard)

    Endogenous Metabolite Cancer
    Cyclic AMP (Standard) is the analytical standard of Cyclic AMP. Cyclic AMP (Cyclic adenosine monophosphate), adenosine triphosphate derivative, is an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. Cyclic AMP is an important second messenger in many biological processes .
    Cyclic AMP (Standard)
  • HY-111673

    8-CPT-cAMP sodium; 8-(p-Chlorophenylthio)-cAMP sodium

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    8-CPT-Cyclic AMP (8-CPT-cAMP) sodium is a selective activator of cyclic AMP-dependent protein kinase (PKA). 8-CPT-Cyclic AMP sodium is also a potent inhibitor of the cyclic GMP-specific phosphodiesterase (PDE VA) with an IC50 of 0.9 μM. 8-CPT-Cyclic AMP sodium also inhibits PDE III and PDE IV with IC50Cyclic AMP sodium is a very high affinity for Epac and is a potent Epac activator .
    8-CPT-Cyclic AMP sodium
  • HY-131763

    2'-O-Monobutyryl cyclic AMP sodium

    Drug Intermediate Others
    2'-O-MB-cAMP (2'-O-Monobutyryl cyclic AM) sodium is an activatable proagent of Cyclic AMP (HY-B1511) .
    2'-O-MB-cAMP sodium
  • HY-121900

    PPAR Metabolic Disease Endocrinology
    LT175, a dual PPARα/γ ligand, is an orally active partial agonist against PPARγ(hPPARα:EC50=0.22 μm; mPPARα:EC50=0.26 μm; hPPARγ:EC50=0.48 μm). LT175 interacts with PPARγ and affects the recruitment of the coregulators cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1). LT175 interacts with PPARγ in a hydrophobic region called “diphenyl pocket”. LT175 has potent insulin-sensitizing effects and reduced adipogenic properties .
    LT175
  • HY-12306
    8-Bromo-cAMP sodium salt
    20+ Cited Publications

    8-Br-CAMP sodium salt

    PKA Apoptosis Cancer
    8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-cAMP sodium salt
  • HY-12306A
    8-Bromo-cAMP
    20+ Cited Publications

    8-Br-CAMP

    PKA Apoptosis Cancer
    8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells .
    8-Bromo-cAMP
  • HY-B1511S

    cyclic adenosine monophosphate-13C5; Adenosine cyclic 3', 5'-monophosphate-13C5; cAMP-13C5

    Isotope-Labeled Compounds Others
    Cyclic AMP- 13C5 is a deuterated cyclic AMP.
    Cyclic AMP-13C5
  • HY-120547

    Adenylate Cyclase Neurological Disease Metabolic Disease
    UCB-11056 is a modulator of cyclic AMP generation. UCB-11056 can rapidly increase cyclic AMP levels in the rat brain in vivo and potentiate stimulated cyclic AMP formation in vitro. UCB-11056 does not stimulate cAMP formation on its own. UCB-11056 is a potential nootropic drug .
    UCB-11056
  • HY-129665

    (±)-O,O-Dimethylcoclaurine

    Endogenous Metabolite Metabolic Disease
    GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K + in rat aortic rings .
    GS-389
  • HY-131421

    8-Piperidino-cyclic AMP

    PKA Cancer
    8-PIP-cAMP is a selective cAMP-dependent protein kinase activator and can be used for study of cancer .
    8-PIP-cAMP
  • HY-W587488

    3′-AMP

    Nucleoside Antimetabolite/Analog Cancer
    Adenosine 3′-monophosphate (3′-AMP), a nucleotide, is a cyclic AMP production agonist .
    Adenosine 3′-monophosphate
  • HY-U00136

    Phosphodiesterase (PDE) Cardiovascular Disease
    Win-62005 is a cyclic AMP phosphodiesterase III (PDE III) inhibitor with Kis of 25 and 26 nM for rat heart and canine aorta, respectively.
    Win-62005
  • HY-W011293

    2,4-Disulfamyl-5-trifluoromethylaniline

    Phosphodiesterase (PDE) Others
    DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase .
    DTA
  • HY-N8209

    Phosphodiesterase (PDE) Inflammation/Immunology
    (+)-Medioresinol Di-O-β-D-glucopyranoside is a lignan glucoside with strong inhibitory activity of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterase .
    (+)-Medioresinol Di-O-β-D-glucopyranoside
  • HY-115732

    PKA Inflammation/Immunology
    PKA-IN-1 is a potent and selective cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK) inhibitor with an IC50 of 0.03 μM .
    PKA-IN-1
  • HY-N1289

    Fungal Phosphodiesterase (PDE) Infection
    Sequosempervirin B, a norlignan isolated from the branches and leaves of Sequoia sempervirens, has antifungal properties. Sequosempervirin B has an inhibitory effect on cyclic AMP phosphodiesterase .
    Sequosempervirin B
  • HY-N7517

    Nucleoside Antimetabolite/Analog Others
    Adenosine 5′-monophosphoramidate sodium is an adenosine derivative and can be used as an intermediate for nucleotide synthesis. Adenosine 5′-monophosphoramidate has a significant effect on the accumulation of cyclic AMP .
    Adenosine 5′-monophosphoramidate sodium
  • HY-P3929

    PKA Cancer
    PKI (14-24)amide is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
    PKI (14-24)amide
  • HY-15979
    H-89
    Maximum Cited Publications
    124 Publications Verification

    PKA Autophagy Neurological Disease
    H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
    H-89
  • HY-P3929A

    PKA Cancer
    PKI (14-24)amide TFA is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .
    PKI (14-24)amide TFA
  • HY-123468

    Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004
  • HY-123468A

    Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 dihydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 dihydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein, and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 dihydrochloride is an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004 di(hydrochloride)
  • HY-B1730
    Phensuximide
    1 Publications Verification

    Others Neurological Disease Metabolic Disease
    Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide
  • HY-108623

    CP-80,633

    Phosphodiesterase (PDE) Inflammation/Immunology
    Atizoram (CP-80,633), a cyclic nucleotide phosphodiesterase (PDE4) inhibitor, elevates plasma cyclic AMP levels and decreases tumor necrosis factor-α (TNFα) production in mice .
    Atizoram
  • HY-112348

    Cyclic GMP-AMP Synthase PKA ERK Calcium Channel Cardiovascular Disease Metabolic Disease
    HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models .
    HA-1004 hydrochloride
  • HY-W011293R

    Phosphodiesterase (PDE) Others
    DTA (Standard) is the analytical standard of DTA. This product is intended for research and analytical applications. DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase .
    DTA (Standard)
  • HY-101962

    Insulin Receptor Metabolic Disease
    HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities
    HNMPA
  • HY-123085

    Isoalloxazine

    Adenosine Receptor Cancer
    Alloxazine is a selective A2b antagonist. Alloxazine completely block 5’N-Ethylcarboxamido adenosine (NECA)-mediated cyclic AMP accumulation with an IC50 of 2.9 μM. Alloxazine can be used for the research of cancer .
    Alloxazine
  • HY-P3777

    Potassium Channel Neurological Disease
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents .
    β-Bag cell peptide
  • HY-B0392

    (+)-Rolipram; (S)-Rolipram

    Phosphodiesterase (PDE) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells .
    (S)-(+)-Rolipram
  • HY-P4012

    Vasopressin Receptor Endocrinology
    [Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture .
    [Asu1,6-Arg8]Vasopressin
  • HY-B0764A
    Bucladesine calcium
    25+ Cited Publications

    Dibutyryl cAMP calcium salt; DBcAMP calcium salt

    PKA Phosphodiesterase (PDE) Apoptosis Others
    Bucladesine calcium salt (Dibutyryl-cAMP calcium salt;DC2797 calcium salt) is a cell-permeable cyclic AMP (cAMP) analog and selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine calcium salt acts as a phosphodiesterase (PDE) inhibitor.
    Bucladesine calcium
  • HY-P3785

    PKA Neurological Disease
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors .
    PKI(5-22)amide
  • HY-P3899

    Somatostatin Receptor Metabolic Disease
    [Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28)
  • HY-B0764
    Bucladesine sodium
    25+ Cited Publications

    Dibutyryl cAMP sodium salt; DBcAMP sodium salt

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .
    Bucladesine sodium
  • HY-B1730R

    Others Neurological Disease Metabolic Disease
    Phensuximide (Standard) is the analytical standard of Phensuximide. This product is intended for research and analytical applications. Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal .
    Phensuximide (Standard)
  • HY-P3899A

    Somatostatin Receptor Metabolic Disease
    [Nle8] Somatostatin (1-28) TFA is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) TFA increases the amylase release.[Nle8] Somatostatin (1-28) TFA increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28) (TFA)
  • HY-122147

    Prostaglandin Receptor Metabolic Disease
    L-644698 is a potent and selective human recombinant prostaglandin D2 (PGD2) receptor (hDP) agonist with Ki values of 0.9, 267, 3730, 9280 nM for hDP, hEP2, hEP3, hEP4, respectively. L-644698 induces cyclic AMP production with an EC50 value of 0.5 nM .
    L-644698
  • HY-P10602

    RII phosphopeptide

    PKA Others
    PKA Regulatory Subunit II Substrate (RII phosphopeptide) is a tool peptide derived from the regulatory subunit Type II (RII) of cyclic AMP-dependent protein kinase (PKA). PKA Regulatory Subunit II Substrate is commonly used to mimic the phosphorylation of protein kinases and as a specific substrate for protein phosphatases to assess the activities of these enzymes .
    PKA Regulatory Subunit II Substrate
  • HY-14428
    ICG-001
    45+ Cited Publications

    β-catenin Apoptosis Cancer
    ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
    ICG-001
  • HY-B0763
    Ibudilast
    5+ Cited Publications

    KC-404; AV-411; MN-166

    Phosphodiesterase (PDE) Inflammation/Immunology Cancer
    Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia .
    Ibudilast
  • HY-B0764R

    PKA Phosphodiesterase (PDE) Inflammation/Immunology
    Bucladesine (sodium) (Standard) is the analytical standard of Bucladesine (sodium). This product is intended for research and analytical applications. Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .
    Bucladesine (sodium) (Standard)
  • HY-N1074

    Scandenolone

    Parasite PKA Infection Inflammation/Immunology
    Warangalone is an anti-malarial compound which can inhibit the growth of both strains of parasite 3D7 (chloroquine sensitive) and K1 (chloroquine resistant) with IC50s of 4.8 μg/mL and 3.7 μg/mL, respectively. Warangalone can also inhibit cyclic AMP-dependent protein kinase catalytic subunit (cAK) with an IC50 of 3.5 μM.
    Warangalone
  • HY-137530

    8-Methylamino-cAMP

    PKA Others
    8-MA-cAMP (8-Methylamino-cAMP) is a cyclic AMP analog that acts as a site-selective PKA agonist with similar affinity for the B site of type I and type II protein kinase A. 8-MA-cAMP is used in conjunction with priming analogs that show site A preference, such as 8-piperidinyl cAMP, to achieve selective stimulation of type I .
    8-MA-cAMP
  • HY-114732

    Adrenergic Receptor Others
    Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes .
    Procaterol
  • HY-123460

    Somatostatin Receptor Cancer
    BN-81674 is a somatostatin analogue and a selective antagonist of the non-peptide human somatostatin sst3 receptor (Ki=0.92 nM). In addition, BN-81674 reversed the inhibition of cyclic AMP accumulation induced by 1 nM somatostatin through the sst3 receptor with an IC50 value of 0.84 nM. BN-81674 can be used in cancer research .
    BN-81674
  • HY-106110

    Prostaglandin Receptor Metabolic Disease
    OP-2507 is a prostacyclin analog. OP-2507 can increase brain glucose levels in mice, suppress the breakdown of energy metabolism under hypoxic conditions, and has a protective effect against changes in cyclic nucleotides in hypoxic brain tissue (specifically, an increase in cyclic AMP and a decrease in cyclic GMP). OP-2507 provides protective effects against brain hypoxia and edema .
    OP-2507
  • HY-128039

    Prostaglandin Receptor Others
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .
    17-Phenyl-ω-trinor-PGE2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: